Tag: population

Photocure and Artera to partner on digital pathology AI test evaluation for Bladder Cancer

OSLO, Norway, June 8, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, and Artera, a leading precision medicine company, announce launch...

CDC Foundation Activates Emergency Response Fund to Support Ebola Response in Democratic Republic of the Congo and Uganda

Flexible Funding Needed to Support the Global Response and Frontline Efforts ATLANTA, June 8, 2026 /PRNewswire/ -- As the Ebola outbreak caused by Bundibugyo virus disease...

National Kidney Foundation and U.S. Pharmacy Organizations Call for Transition to Race-Agnostic eGFR in Medication Decision-Making

NEW YORK, June 8, 2026 /PRNewswire/ -- A coalition of leading U.S. pharmacy organizations, in collaboration with the National Kidney Foundation (NKF), is urging...

Liquid-applied Membrane Market worth $35.47 billion by 2031 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., June 8, 2026 /PRNewswire/ -- According to MarketsandMarkets, "Liquid-applied Membrane Market by Type (Bituminous, Elastomeric, Cementitious), Application (Roofing, Walls, Roadways), Usage (New...

Liquid-applied Membrane Market worth $35.47 billion by 2031 – Exclusive Report by MarketsandMarkets™

DELRAY BEACH, Fla., June 8, 2026 /PRNewswire/ -- According to MarketsandMarkets, "Liquid-applied Membrane Market by Type (Bituminous, Elastomeric, Cementitious), Application (Roofing, Walls, Roadways), Usage (New...

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027

The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment...

Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while...

Company announcement No. 21 / 2026

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting...

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.^2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),²and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).⁴ Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.^5,6

Lilly’s Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage...

In ATTAIN-1, women in perimenopause taking Foundayo lost up to 30.4 lbs (14.4%) and those in post-menopause lost up to 28.2 lbs (14.1%)In ATTAIN-2, women taking Foundayo lost significant...

Communiqué Orange : Signing of a Memorandum of Understanding for the acquisition of SFR

Press release
Paris, 6 June 2026

Communiqué Orange : Signature d’un protocole d’accord en vue de l’acquisition de SFR

Communiqué de presse
Paris, le 6 juin 2026

Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association’s 2026 Scientific Sessions

Post hoc analyses explored the impact of semaglutide across an array of conditions including obstructive sleep apnea (OSA), asthma-related adverse outcomes, liver health, cardiometabolic...

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978

Amaero Re-domiciliation: Schemes Become Effective

Willis launches risk program for wood frame construction projects

O2 与 Mavenir 成功试验一项新技术，可提升听障人士的通话清晰度

Photocure and Artera to partner on digital pathology AI test evaluation for Bladder Cancer

CDC Foundation Activates Emergency Response Fund to Support Ebola Response in Democratic Republic of the Congo and Uganda

National Kidney Foundation and U.S. Pharmacy Organizations Call for Transition to Race-Agnostic eGFR in Medication Decision-Making

Liquid-applied Membrane Market worth $35.47 billion by 2031 – Exclusive Report by MarketsandMarkets™

Liquid-applied Membrane Market worth $35.47 billion by 2031 – Exclusive Report by MarketsandMarkets™

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while...

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting...

Lilly’s Foundayo (orforglipron), the only oral GLP-1 taken without food or water restrictions, was associated with significant weight loss in women at every stage...

Communiqué Orange : Signing of a Memorandum of Understanding for the acquisition of SFR

Communiqué Orange : Signature d’un protocole d’accord en vue de l’acquisition de SFR

Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association’s 2026 Scientific Sessions

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Explore

Press Releases

News & Opinion

Living

Others

Follow us